Charles River lifts 2026 guidance as organic growth returns

Charles River Laboratories International, Inc. (NYSE:CRL) raised its 2026 guidance after organic revenue growth accelerated to 4.7% in the third quarter, marking a second consecutive quarter of underlying growth. The reported numbers were less flattering: revenue fell 2.2% to US$982.7 million, mainly because of businesses divested in May, while non-GAAP diluted earnings per share climbed 27.2% to US$3.09.

Guidance rises on stronger organic performance

The contract research and laboratory services company now expects 2026 organic revenue growth of at least 1.5%, up from its previous range of 0% to 1%. Reported revenue is still expected to decline between 2.0% and 1.5%, reflecting the effect of divestitures. Non-GAAP EPS guidance increased to US$11.35-US$11.55, from US$11.15-US$11.45 previously.

Charles River attributed the upgrade primarily to third-quarter outperformance, particularly in its Discovery and Safety Assessment, or DSA, segment, and to a lower tax rate. The company also lifted its GAAP EPS guidance to US$8.15-US$8.35, although that range includes the substantial tax benefit recognised during the quarter.

DSA and Manufacturing provide the operating lift

DSA revenue declined 0.7% to US$596.3 million on a reported basis, but organic revenue increased 5.9% as regulated safety assessment study volumes improved. Its non-GAAP operating margin rose to 26.8% from 25.4%, helped by operating leverage and lower sourcing costs for large research models.

Manufacturing Solutions produced the strongest organic growth in the portfolio, with revenue up 7.4% organically despite reported revenue falling 6.2% to US$178.9 million after the CDMO divestiture. Its non-GAAP operating margin expanded to 38.6% from 26.7%, with the company citing the divestiture and related operating benefits. Research Models and Services remained the weak point: organic revenue fell 0.6%, with lower North American small-model revenue and weaker large-model demand only partly offset by growth in China and research model services.

GAAP profit includes a major tax windfall

GAAP net income attributable to common shareholders rose to US$333.1 million from US$54.4 million, while diluted GAAP EPS increased to US$6.86 from US$1.10. That comparison is unusually flattering: Charles River recorded a US$245.6 million, or US$5.06 per share, benefit from reversing acquired tax reserves after newly enacted tax legislation and the completion of certain foreign tax requirements.

The non-GAAP result provides a cleaner view of the quarter’s operating performance, though it is not free of judgement. Non-GAAP net income reached US$150.1 million, up from US$120.3 million, and non-GAAP operating margin widened to 23.0% from 19.7%. The company’s adjustments exclude acquisition and divestiture costs, amortisation, restructuring charges, investment gains and losses, and various tax effects, so the measure should not be treated as a substitute for US GAAP.

Strategic initiatives move from presentation to execution

Alongside the results, Charles River outlined its Pathway to Purpose strategy and Create the Future initiative, focused on operational efficiency, scientific capabilities and deeper client relationships. It also highlighted an automated Endosafe cartridge manufacturing suite, a laboratory workflow partnership with Autolomous, and collaboration with the US Food and Drug Administration to validate preclinical tools for assessing the abuse potential of new drugs.

Those initiatives remain longer-dated than the guidance upgrade. The nearer test is whether DSA bookings and proposals, which the company said continued to show robust year-on-year increases, can translate into sustained revenue growth while Research Models and Services stabilises. The balance sheet also deserves attention: long-term debt and finance leases stood at US$2.44 billion at September 26, up from US$2.14 billion at the end of 2025.